News & Events


Prof. Brotzu’s hair loss remedy

An update from Fidia Farmaceutici

Further to previous communications, regarding the development of a hair loss remedy initiated a few months ago, we announce that the study is still in progress, thereby an accurate time frame in which such remedy would be available cannot be defined yet. Being a pharmaceutical manufacturing company…

HYMOVIS® Receives Permanent, Product-Specific J-Code from the Center for Medicare and Medicaid Services (CMS)

HYMOVIS® offers a convenient two-dose regimen

Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services (“CMS”) has assigned its product HYMOVIS® a unique Healthcare Common…

Fidia farmaceutici’s collagenase has been granted Orphan Drug Designation

Designation by the US FDA for the treatment of advanced Dupuytren’s disease

Abano Terme, October 18, 2016 - Fidia Farmaceutici announced the obtainment of Orphan Drug Designation by the US Food and Drug Administration, for its Vibrio alginolyticus collagenase, produced and purified in the R&D Unit in Noto (Sicily), for the treatment of advanced Dupuytren’s disease…

Fidia farmaceutici to attend the WUWHS Congress in Florence

A highly innovative and valuable contribution to healthcare professionals who work in contact with skin wounds

Fidia Farmaceutici SpA will take part in the 5th World Congress of the World Union of Wound Healing Societies "One Vision, One Mission”, in Florence, September 25-29 2016. WUWHS 2016 will offer an extensive scientific program including numerous symposia, training sessions, workshops and focus…

Fidia's 70th Anniversary

Born in Italy, globally successful

Fidia Farmaceutici celebrates its 70th Anniversary - the company was born in 1946, with great expectations and energy, as did Italy on the brink of a new era. It was 1946. We take pride in the things we do and are definitely proud of what we have achieved, along an 70-year incredible journey that…

Biofarmitalia is part of Fidia Pharma Group's family of companies

For almost 20 years, Biofarmitalia has been designing, formulating and manufacturing its own products.

Founded in 1992 to develop new technologies for cosmetic and pharmaceutical applications, Biofarmitalia has gained expertise in doing research and manufacturing patches and dynamic devices designed for oral, dermal and transdermal controlled-release formulations of active ingredients. The…

FIDIA Farmaceutici to Attend the 26th EWMA Conference in Bremen

An opportunity to showcase FIDIA's unique products in the wound healing area

FIDIA Farmaceutici S.p.A., the Italian pharmaceutical company leader in hyaluronic acid (HY) - based products, will be present at the 26th Conference of the European Wound Management Association (EWMA), May 11-13, 2016 at the Messe Bremen (Germany). The EWMA conference offers high level scientific…

Fidia at the Wings for Life World Run: running for those who can’t.

Fidia Farmaceutici is partner in this global running event.

Fidia Farmaceutici will participate for the first time in the “Wings for Life World Run” in Milan, Sunday, May 8 2016. The Wings for Life World Run is a global charity race: the whole world running together to raise money and awareness for Wings for Life, a foundation with the single-minded…

Fidia Farmaceutici has now a subsidiary in the Middle East

Fidia Farmaceutici has established a wholly owned subsidiary in Middle East, further enhancing its presence in growing markets.

Continuing its International growth, Fidia farmaceutici, a world leader in hyaluronic acid R&D and manufacturing, announces the opening of a wholly owned subsidiary in the United Arab Emirates. A hub for its operations in the Middle East and North Africa (MENA), Fidia’s 6th subsidiary will be based…

Fidia Introduces Hymovis®, a Next-Generation Hyaluronan, at the AAOS Annual Meeting in Orlando

Hymovis®, which is being launched in the U.S, is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties

PARSIPPANY, N.J., February 25, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., will introduce Hymovis® (high molecular weight viscoelastic hyaluronan) at…


Find out more about Fidia’s product portfolio:

Go to the website

Fidia worldwide

Direct links to access Fidia’s international websites:

Follow us:

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint healthcare
- advanced wound care
- dermatology
- neurology
- dermo-aesthetics